Citadel Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.4M | Sell |
60,100
-8,600
| -13% | -$1.5M | ﹤0.01% | 3079 |
|
|
2025
Q4 | $11.7M | Buy |
68,700
+60,800
| +770% | +$9.32M | ﹤0.01% | 3064 |
|
|
2025
Q3 | $1.04M | Buy |
7,900
+3,800
| +93% | +$456K | ﹤0.01% | 7454 |
|
|
2025
Q2 | $435K | Sell |
4,100
-4,700
| -53% | -$511K | ﹤0.01% | 8954 |
|
|
2025
Q1 | $1.09M | Buy |
8,800
+200
| +2% | +$26.1K | ﹤0.01% | 6761 |
|
|
2024
Q4 | $1.06M | Sell |
8,600
-5,600
| -39% | -$660K | ﹤0.01% | 6888 |
|
|
2024
Q3 | $1.58M | Sell |
14,200
-3,100
| -18% | -$340K | ﹤0.01% | 5950 |
|
|
2024
Q2 | $1.85M | Buy |
17,300
+2,600
| +18% | +$286K | ﹤0.01% | 5467 |
|
|
2024
Q1 | $1.77M | Sell |
14,700
-20,000
| -58% | -$2.45M | ﹤0.01% | 5768 |
|
|
2023
Q4 | $4.27M | Buy |
34,700
+20,700
| +148% | +$2.58M | ﹤0.01% | 4038 |
|
|
2023
Q3 | $1.81M | Sell |
14,000
-2,900
| -17% | -$386K | ﹤0.01% | 5400 |
|
|
2023
Q2 | $2.1M | Buy |
16,900
+4,900
| +41% | +$659K | ﹤0.01% | 5074 |
|
|
2023
Q1 | $1.76M | Sell |
12,000
-1,248
| -9% | -$185K | ﹤0.01% | 5633 |
|
|
2022
Q4 | $2.11M | Sell |
13,248
-2,900
| -18% | -$425K | ﹤0.01% | 5380 |
|
|
2022
Q3 | $2.15M | Buy |
16,148
+9,300
| +136% | +$1.41M | ﹤0.01% | 5449 |
|
|
2022
Q2 | $1.07M | Sell |
6,848
-5,400
| -44% | -$831K | ﹤0.01% | 6870 |
|
|
2022
Q1 | $1.91M | Sell |
12,248
-47,076
| -79% | -$6.83M | ﹤0.01% | 6194 |
|
|
2021
Q4 | $7.56M | Buy |
59,324
+15,624
| +36% | +$2.05M | ﹤0.01% | 3560 |
|
|
2021
Q3 | $5.69M | Sell |
43,700
-67,804
| -61% | -$10.2M | ﹤0.01% | 4060 |
|
|
2021
Q2 | $19.8M | Buy |
111,504
+4
| +0% | +$693 | ﹤0.01% | 2093 |
|
|
2021
Q1 | $18.3M | Buy |
111,500
+80,400
| +259% | +$13.2M | ﹤0.01% | 2084 |
|
|
2020
Q4 | $5.13M | Sell |
31,100
-18,400
| -37% | -$2.74M | ﹤0.01% | 3636 |
|
|
2020
Q3 | $7.06M | Sell |
49,500
-2,000
| -4% | -$248K | ﹤0.01% | 2691 |
|
|
2020
Q2 | $5.68M | Buy |
51,500
+27,500
| +115% | +$3.04M | ﹤0.01% | 2912 |
|
|
2020
Q1 | $2.39M | Buy |
24,000
+7,800
| +48% | +$1.01M | ﹤0.01% | 3861 |
|
|
2019
Q4 | $2.42M | Buy |
16,200
+2,200
| +16% | +$299K | ﹤0.01% | 4105 |
|
|
2019
Q3 | $1.79M | Sell |
14,000
-500
| -3% | -$67K | ﹤0.01% | 4656 |
|
|
2019
Q2 | $2.07M | Sell |
14,500
-9,900
| -41% | -$1.33M | ﹤0.01% | 4458 |
|
|
2019
Q1 | $3.49M | Buy |
24,400
+10,900
| +81% | +$1.42M | ﹤0.01% | 3517 |
|
|
2018
Q4 | $1.67M | Sell |
13,500
-24,500
| -64% | -$3.63M | ﹤0.01% | 4430 |
|
|
2018
Q3 | $6.39M | Sell |
38,000
-8,300
| -18% | -$1.43M | ﹤0.01% | 2666 |
|
|
2018
Q2 | $7.98M | Buy |
46,300
+25,400
| +122% | +$4.15M | ﹤0.01% | 2182 |
|
|
2018
Q1 | $3.16M | Sell |
20,900
-16,800
| -45% | -$2.46M | ﹤0.01% | 3079 |
|
|
2017
Q4 | $5.08M | Sell |
37,700
-4,300
| -10% | -$596K | ﹤0.01% | 2468 |
|
|
2017
Q3 | $6.14M | Buy |
42,000
+2,000
| +5% | +$302K | ﹤0.01% | 2089 |
|
|
2017
Q2 | $6.22M | Buy |
40,000
+11,200
| +39% | +$1.71M | 0.01% | 1890 |
|
|
2017
Q1 | $4.18M | Sell |
28,800
-1,400
| -5% | -$182K | ﹤0.01% | 2226 |
|
|
2016
Q4 | $3.29M | Sell |
30,200
-15,500
| -34% | -$1.73M | ﹤0.01% | 2395 |
|
|
2016
Q3 | $5.55M | Buy |
45,700
+9,000
| +25% | +$1.21M | 0.01% | 1870 |
|
|
2016
Q2 | $5.19M | Sell |
36,700
-22,200
| -38% | -$3.27M | 0.01% | 1791 |
|
|
2016
Q1 | $7.69M | Sell |
58,900
-9,200
| -14% | -$1.15M | 0.01% | 1398 |
|
|
2015
Q4 | $9.57M | Buy |
68,100
+8,800
| +15% | +$1.22M | 0.01% | 1314 |
|
|
2015
Q3 | $7.88M | Sell |
59,300
-10,600
| -15% | -$1.83M | 0.01% | 1524 |
|
|
2015
Q2 | $12.3M | Sell |
69,900
-15,000
| -18% | -$2.69M | 0.01% | 1331 |
|
|
2015
Q1 | $14.7M | Buy |
84,900
+6,900
| +9% | +$1.18M | 0.01% | 1169 |
|
|
2014
Q4 | $12.8M | Buy |
78,000
+21,000
| +37% | +$3.49M | 0.01% | 1230 |
|
|
2014
Q3 | $9.15M | Buy |
57,000
+1,500
| +3% | +$231K | 0.01% | 1442 |
|
|
2014
Q2 | $8.16M | Sell |
55,500
-34,100
| -38% | -$4.73M | 0.01% | 1427 |
|
|
2014
Q1 | $12.4M | Buy |
89,600
+58,300
| +186% | +$8.78M | 0.01% | 1128 |
|
|
2013
Q4 | $3.96M | Sell |
31,300
-6,400
| -17% | -$662K | 0.01% | 1869 |
|
|
2013
Q3 | $3.47M | Buy |
37,700
+8,700
| +30% | +$702K | 0.01% | 1899 |
|
|
2013
Q2 | $1.99M | Buy |
+29,000
| New | +$1.77M | ﹤0.01% | 2495 |
|
Other funds holding JAZZ
VPM
VCM
EC
Citadel Advisors's JAZZ Position: Q1 2026 in Review
Citadel Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 305% in Q1 2026, buying an estimated $166M and bringing the position to 1,259,444 shares worth $238M. The position accounts for 0.04% of the portfolio, ranked #379.
Citadel Advisors first reported a position in JAZZ in Q2 2013 and has held it in 51 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Citadel Advisors held 1,259,444 shares of Jazz Pharmaceuticals worth $238M as of Q1 2026.
- Citadel Advisors bought 948,324 Jazz Pharmaceuticals shares in Q1 2026, an estimated $166M.
- Jazz Pharmaceuticals made up 0.04% of Citadel Advisors's portfolio in Q1 2026, its #379 holding.
- Citadel Advisors first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.